for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brickell Biotech Inc

BBI.N

Latest Trade

0.32USD

Change

0.01(+1.65%)

Volume

560

Today's Range

0.31

 - 

0.32

52 Week Range

0.30

 - 

1.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.31
Open
0.31
Volume
560
3M AVG Volume
49.24
Today's High
0.32
Today's Low
0.31
52 Week High
1.69
52 Week Low
0.30
Shares Out (MIL)
115.05
Market Cap (MIL)
37.66
Forward P/E
-0.61
Dividend (Yield %)
--

Next Event

Q4 2021 Brickell Biotech Inc Earnings Release

Latest Developments

More

Brickell Biotech Reports Third Quarter 2021 Financial Results And Provides Corporate Update

Brickell Biotech Inc Prices Public Offering Of Common Stock

Brickell Biotech Announces Proposed Underwritten Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brickell Biotech Inc

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company. The Company focuses on the development of therapeutics for the treatment of skin diseases. The Company's Phase III clinical-stage investigational product candidate, sofpironium bromide, is a chemical entity that belongs to a class of medications called anticholinergics is for the treatment of primary axillary (underarm) hyperhidrosis. The Company is also conducting early research programs targeting various skin diseases.

Industry

Biotechnology & Drugs

Contact Info

5777 Central Ave Ste 102

BOULDER, CO

80301-2870

United States

+1.720.5054755

https://brickellbio.com/

Executive Leadership

Reginald L. Hardy

Chairman of the Board, Co-Founder

Robert B. Brown

Chief Executive Officer, Director

Andrew D. Sklawer

Co-Founder, Chief Operating Officer, Secretary

Albert N. Marchio

Chief Financial Officer

Jose Breton

Chief Accounting Officer, Controller

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-5.180

2019

-4.500

2020

-0.850

2021(E)

-0.525
Price To Earnings (TTM)
--
Price To Sales (TTM)
115.15
Price To Book (MRQ)
1.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-209.76
Return on Equity (TTM)
-161.18

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up